Matt Herper
Senior editor, STAT News
“We're dealing with an FDA that's really been decimated and has lost a lot of seasoned people. And that makes it a lot harder to be, instead of lax or tough, just get it right.”
“The track record of new technology in drug development is it makes it more expensive.”
Matt Herper
One-line summary: STAT News senior editor; on Biotech Hangout provides the FDA-capacity-depletion falsifier to the rare-disease right-shift.
What they're known for
Brief factual context — fill in.
Why they matter to stock-market
Why this person's claims are tracked here — fill in.
Said
Speaker-attributed claims extracted from diarized sources. Each bullet mirrors one entry in quotes: frontmatter — keep them in sync.
-
On fda-rare-disease-regulatory-right-shift, fda-right-shift-to-rare-disease-refile-rerate:
"We're dealing with an FDA that's really been decimated and has lost a lot of seasoned people. And that makes it a lot harder to be, instead of lax or tough, just get it right." — 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026 (2026-07-10)
-
On fda-rare-disease-regulatory-right-shift:
"The track record of new technology in drug development is it makes it more expensive." — 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026 (2026-07-10)
Sources
Related
Cross-links — fill in.